AGRX:NSD-Agile Therapeutics, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 2.78

Change

0.00 (0.00)%

Market Cap

USD 0.24B

Volume

1.08M

Average Target Price

USD 10.00 (+259.71%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD9.99B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 32.94 11.89
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

N/A

USD2.82B 44.31 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.75B 22.85 62.06
APHA Aphria Inc

N/A

USD2.03B 57.50 454.68
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.86B 16.83 13.97
ATNX Athenex, Inc

N/A

USD1.28B N/A N/A
ENDP Endo International plc

N/A

USD1.22B N/A 9.47
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.12B 8.62 5.57

ETFs Containing AGRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.20% 76% C 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.20% 76% C 61% D-
Trailing 12 Months  
Capital Gain 34.95% 86% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.95% 86% B 73% C
Trailing 5 Years  
Capital Gain -68.48% 37% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.48% 37% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 24.28% N/A N/A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.28% N/A N/A 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 116.49% N/A N/A 7% F
Risk Adjusted Return 20.84% N/A N/A 46% F
Market Capitalization 0.24B 53% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.74 43% F 36% F
Price / Cash Flow Ratio -15.49 90% A- 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -82.12% 43% F 14% F
Return on Invested Capital -57.07% 36% F 17% F
Return on Assets -38.96% 19% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.83 52% F 35% F
Short Percent 4.88% 58% F 40% F
Beta 1.44 42% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.